Portfolio timeline
Baker Bros. Advisors — Portfolio History
Every 13F quarter on record, newest first. Each row lists the quarter's top positions; open any quarter for the full portfolio, buys, adds, trims and exits.
- Quarters
- 4
- Avg positions
- 83.5
- Latest top 5 weight
- 58.5%
- Avg top 5 weight
- 53.8%
- Avg changed names
- 37.7
- Held in ≥75% of stored quarters
- 75
Quarter Activity
Reported increases, decreases, exits, and new positions vs. the prior filing.
| Quarter | New | Adds | Trims | Exits | Top 5 |
|---|---|---|---|---|---|
| Q3 2026 | 5 | 9 | 11 | 9 | 58.5% |
| Q2 2026 | 8 | 16 | 7 | 8 | 52% |
| Q1 2026 | 7 | 18 | 6 | 9 | 50.5% |
| Q4 2025 | No prior baseline | 54.2% | |||
Most Frequently Reported Positions
Positions appearing across the most stored reporting quarters.
| Position | Quarters | Latest weight | Latest value |
|---|---|---|---|
| INCY Incyte Corp. | 4 | 17.7% | $3.7B |
| ONC Beigene Ltd-Adr | 4 | 15.4% | $3.2B |
| RVMD Revolution Medicines | 4 | 10.4% | $2.2B |
| KOD Kodiak Sciences Inc. | 4 | 9.9% | $2.1B |
| MDGL Madrigal Pharmaceuticals Inc. | 4 | 5.1% | $1.1B |
| INSM Insmed Inc. | 4 | 4.8% | $1.0B |
Tip: hover any ticker below to see its weight in that quarter's portfolio.